The effect of hydrochloric, malic and succinic salts of 2-ethyl-6-methyl-3-oxypyridine on ­self-­assessment of depression manifestations in women receiving radiotherapy after surgical ­treatment of uterine cancer

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Background. The detection of cancer and its subsequent treatment contribute to the development of depression. This circumstance illustrates the need for proactive prevention of affective status disorders in cancer patients, its dynamic control and timely correction.

Aim. Comparative analysis of the effect of hydrochloric, malic and succinic salts of 2-ethyl-6-methyl-3-oxypyridine (methylethylpyridinol, ethylmethylhydroxypyridine malate, ethylmethylhydroxypyridine succinate) on the dynamics of self-assessment of depression manifestations in women recieving radiation therapy after surgical treatment of uterine cancer.

Material and methods. A short-term, prospective, simple “blind”, placebo-controlled, randomized study of the effect of methylethylpyridinol, ethylmethylhydroxypyridine malate and ethylmethylhydroxypyridine succinate on the severity of depression symptoms in patients receiving radiation therapy after extended extirpation of the uterus with appendages was performed. The study was completed by 96 patients. Course two-week administration of drugs in almost equimolar single doses (0.83–0.88 mmol) was started simultaneously with radiation therapy. The treatment effectiveness was assessed using the Beck Depression Inventory 2 and 4 weeks after the start of the study. Statistical comparison of related samples was carried out using the Friedman test and post hoc analysis using the paired Wilcoxon test with the Bonferroni correction. Independent samples were compared using the Kruskal–Wallis test with a post hoc analysis using the Dan–Bonferroni test.

Results. Radiation therapy was found to cause a clinically significant increase in the severity of depressive symptoms in 14 and 28 days after the start of the study (p ≤0.010). Two-week administration of methylethylpyridinol, ethylmethylhydroxypyridine malate, and ethylmethylhydroxypyridine succinate reduced the severity of depressive symptoms to the normal level (p <0.001), mainly due to a decrease in the severity of symptoms of the cognitive-affective cluster (p <0.001). The studied drugs with equal severity prevented the escalation of depression symptoms according to the Beck Depression Inventory (p ˃0.05).

Conclusion. Hydrochloric, malic and succinic salts of 2-ethyl-6-methyl-3-oxypyridine are equally effective in preventing the development of depression during postoperative radiation treatment of patients with ute-rine cancer.

Full Text

Restricted Access

About the authors

Ilya A. Volchegorskii

South Ural State Medical University

ORCID iD: 0000-0003-3186-3960

M.D., D. Sci. (Med.), Prof., Head of Depart., Depart. of Pharmacology

Russian Federation, Chelyabinsk, Russia

Andrey V. Vazhenin

South Ural State Medical University

ORCID iD: 0000-0002-7807-8479

M.D., D. Sci. (Med.), Prof., Acting Rector, Head of Depart., Depart. of Oncology, Radiation Diagnostics and Radiation Therapy

Russian Federation, Chelyabinsk, Russia

Anna P. Alekseeva

South Ural State Medical University; Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine

Author for correspondence.
ORCID iD: 0000-0002-6621-0284

PhD Stud., Depart. of Pharmacology; Clinical Pharmacologist

Russian Federation, Chelyabinsk, Russia; Chelyabinsk, Russia


  1. Grassi L. Psychiatric and psychosocial implications in cancer care: the agenda of psycho-oncology. Epidemiol Psychiatr Sci. 2020;29:89. doi: 10.1017/S2045796019000829.
  2. Zubkova YuN, Kurmukov IA, Obukhova OA, Kashia ShR. The relevance of the use of psychotropic drugs in clinical oncology. Pharmateka. 2018;(12):14–20. (In Russ.) doi: 10.18565/pharmateca.2018.12.14-20.
  3. Kondratyeva KO, Semiglazova TYu, Kasparov BS, Vagaitseva MV, Klyuge VA. Antivital experiences of oncologic patients against the background of antitumor treatment and in the long term period. Pharmateka. 2020;27(7):76–80. (In Russ.) doi: 10.18565/pharmateca.2020.7.76-80.
  4. Volchegorskii IA, Vazhenin AV, Zyuzina MS. The effect of derivatives of 3-hydroxypyridine and succinic acids on depressive symptoms, pain intensity and quality of life after surgical treatment of breast cancer. Journal of Modern Oncology. 2018;20(1):54–59. (In Russ.) doi: 10.26442/1815-1434_20.1.54-59.
  5. Volchegorskii IA, Mester KM. Effects of 3-hydroxypyridine and succinic acid derivatives on the dynamics of dorsalgia and affective disorders after surgical treatment of discs herniation. Eksperimentalnaya i klinicheskaya farmakologiya. 2010;73(1):33–39. (In Russ.) doi: 10.30906/0869-2092-2010-73-1-33-39.
  6. Volchegorskiy IA, Vazhenin AV, Zyuzina MS. Comparative analysis of the influence of 3-hydroxypyridine and succinic acid on the severity of pain and depressive symptoms after oncomammological intervention. Eksperimentalnaya i klinicheskaya farmakologiya. 2018;12(81):29–34. (In Russ.) doi: 10.30906/0869-2092-2018-81-12-29-34.
  7. Dvoyrin VV, Klimenkov AA. Metodika kontroliruemykh klinicheskikh ispytaniy. (Method of controlled clinical trials.) Moscow: Meditsina; 1985. 143 p. (In Russ.)
  8. Avedisova AS, Chakhava VO, Lyupaeva NV. Placebo effect in psychiatry (literature review). Russian journal of psychiatry. 2003;(3):65–71. (In Russ.)
  9. Belova AN. Shkaly, testy i oprosniki v nevrologii i neyrokhirurgii. (Scales, tests and questionnaires in neurology and neurosurgery.) 3rd ed. M.: Prakticheskaya meditsina; 2018. 696 p. (In Russ.)
  10. Andryushchenko AV, Drobizhev MYu, Dobrovol'skiy AV. Comparative evaluation of the CES-D, BDE and HADS(d) scale in the diagnosis of depression in general medical practice. Zhurnal nevrologii i psikhiatrii im SS Korsakova. 2003;103(5):11–18. (In Russ.)
  11. Novik AA, Ionova TI, Kalyadina SA, Kishtovich AV. Symptom assessment in patients with hematological malignancies: discrepancies in estimation of symptom severity and symptom management efficacy between a patient and a physician. Clinical oncohematology. 2008;1(3):238–245. (In Russ.)
  12. Смулевич А.Б. Депрессии при психических и соматических заболеваниях. Изд. 4-е, перераб. и доп. М.: Медицинское информационное агентство; 2015. 640 с. [Smulevich AB. Depressii pri psikhicheskikh i somaticheskikh zabolevaniyakh. (Depression in mental and somatic diseases.) 4th ed. Moscow: Meditsinskoe informatsionnoe agentstvo; 2015. 640 p.
  13. Holub K, Vargas A, Biete A. Radiation-induced lymphopenia: the main aspects to consider in immunotherapy trials for endometrial and cervical cancer patients. Clin Trans Oncol. 2020;22(11):2040–2048. doi: 10.1007/s12094-020-02345-3.
  14. Volchegorskii IA, Miroshnichenko IYu, Rassohina LM, Faizullin RM. Experimental study of 3-oxypiridine and succinic acid derivates antidepressant activity in mice. Eksperimentalnaya i klinicheskaya farmakologiya. 2013;76(7):6–10. (In Russ.) doi: 10.30906/0869-2092-2013-76-7-6-10.
  15. Volchegorskii IA, Sinitskii AI, Miroshnichenko IYu, Rassokhina LM. Effects of 3-hydroxypyridine and succinic acid derivatives on monoamine oxidase activity in vitro. Pharmaceutical Chemistry Journal. 2018;52(1):3–7. (In Russ.) doi: 10.1007/s11094-018-1760-2.

Supplementary files

There are no supplementary files to display.

© 2022 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies